XL-999

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameXL-999
Drug Alias NameXL-999EXEL-0999
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 3 antagonistsVascular endothelial growth factor receptor antagonistsFibroblast growth factor receptor 1 antagonists +[5] 
TargetsPlatelet-derived growth factor receptor betaFibroblast growth factor receptor 1Fibroblast growth factor receptor 3 +[5] 
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsColorectal Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline PlcSymphony Evolution IncExelixis Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSymphony Evolution Inc
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsColorectal Neoplasms +[7] 

Other Information

ATC CodeN/A
Related LinksDrugBank